HR Execs on the Move

Codexis

www.codexis.com

 
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company`s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.codexis.com
  • 200 Penobscot Drive
    Redwood City, CA USA 94063
  • Phone: 650.421.8100

Executives

Name Title Contact Details
Lyndsey Clogston
Director, HR and Talent Management Profile
Svetlana Sowers
Director, OEM Sales Profile
Catherine Mesgar
Senior Director, People Operations and Technology Profile

Similar Companies

Resilience Technology Corporation

Resilience is changing the way medicine is made – leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.

BioWa

BioWa is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NewNeural

NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

EGEN

EGEN is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.